Abstract
Angiotensin-converting enzyme inhibitors and beta-blockers are the main therapies used in the treatment of symptomatic systolic heart failure. In practice, those two groups are usually used simultaneously because of their complementary mechanism and effect. Current guidelines limit the list of recommended drugs to those, that were successfully tested in large randomised trials. In addition, they provide optimal dosage that was used in these studies. This article presents a summary of the current recommendations in this topic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
